A phase I/2, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability and efficacy of BMN 110 in subjects with mucopolysaccharidosis IVA [Morquio A syndrome] - Christian Hendriksz

<< Return to Program Page

 

 

This video clips required the Adobe Flash plug-in for your browser. Please download here.